Mayne Pharma Group Stock Today
| MAYNF Stock | USD 3.10 0.10 3.33% |
Performance4 of 100
| Odds Of DistressOver 59
|
Mayne Pharma is trading at 3.10 as of the 11th of December 2024. This is a 3.33 percent increase since the beginning of the trading day. The stock's lowest day price was 2.85. Mayne Pharma has over 59 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 11th of November 2024 and ending today, the 11th of December 2024. Click here to learn more.
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia. The company has 1.74 B outstanding shares. More on Mayne Pharma Group
Moving against Mayne Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Mayne Pink Sheet Highlights
| President of Mayne Pharma USA | Stefan Cross |
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
Mayne Pharma Group [MAYNF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Small-Cap' category with a current market capitalization of 235.41 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Mayne Pharma's market, we take the total number of its shares issued and multiply it by Mayne Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Mayne Pharma Group classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 1.74 B outstanding shares.
Mayne Pharma Group has accumulated about 98.01 M in cash with (7.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06.
Check Mayne Pharma Probability Of Bankruptcy
Ownership AllocationMayne Pharma Group maintains a total of 1.74 Billion outstanding shares. Mayne Pharma Group holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Mayne Ownership Details
Mayne Pharma Group Risk Profiles
| Mean Deviation | 1.47 | |||
| Standard Deviation | 4.18 | |||
| Variance | 17.48 | |||
| Risk Adjusted Performance | 0.0521 |
Mayne Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Mayne Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
| All Next | Launch Module |
Mayne Pharma Corporate Management
| Kimberly JD | Exec Counsel | Profile | |
| Shawn BSc | MD CEO | Profile | |
| Hemanshu Pandya | VP Division | Profile | |
| Daniel Moore | Ex Solutions | Profile | |
| Aaron Gray | Chief Officer | Profile | |
| Brant Schofield | Exec Devel | Profile |
Other Information on Investing in Mayne Pink Sheet
Mayne Pharma financial ratios help investors to determine whether Mayne Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mayne with respect to the benefits of owning Mayne Pharma security.